PTEN Loss in Prostate Cancer: An Educational Guide to a Prognostic Biomarker

A pathologist reviewing a prostatectomy for a Gleason 4+4 tumor faces a recurring question: does the molecular biology of this cancer match its architecture, or is something more aggressive hiding beneath a middling grade? PTEN loss is one of the answers that molecular pathology can offer. When a prostate cancer loses PTEN, it tends to behave worse than its grade alone would predict — and that single observation has made PTEN one of the most studied prognostic markers in the disease [1,2].

This article walks through what the test measures, how we run it, what each result means, and where the evidence is still unsettled.

What the Test Measures

PTEN — phosphatase and tensin homolog — is a tumor suppressor. Its job is to put the brakes on a growth-signaling cascade called the PI3K/AKT pathway. In a normal cell, PTEN removes a phosphate group from a key lipid signal, and that quiet chemical act keeps the pathway idling rather than racing. Lose PTEN, and the brakes come off.

When both copies of the PTEN gene are inactivated — through deletion, mutation, or other mechanisms — the pathway runs unchecked. Cells proliferate more readily, resist apoptosis, and acquire the survival advantages that let a tumor progress. This deregulation drives more aggressive tumor behavior, and in prostate cancer it correlates with higher grade, advanced stage, and a greater chance of recurrence after treatment [2].

That's the core biology. The test's whole purpose is to detect whether that brake is still in place.

How It's Tested

Two assay approaches dominate, and they interrogate different aspects of the same problem.

Immunohistochemistry (IHC) is the workhorse. It measures the PTEN protein directly. A pathologist stains a formalin-fixed, paraffin-embedded (FFPE) tissue section and looks for whether tumor cells still express PTEN. Scoring here is deceptively simple in concept: PTEN is either present in the tumor cells or it's absent. The elegance of the IHC approach lies in its built-in internal control. Adjacent benign glands, stroma, and endothelial cells retain PTEN, so they stain positive right alongside the tumor. If the tumor cells go blank while the surrounding normal tissue stains crisply, you've got genuine, interpretable loss.

In practice, the IHC internal control is one of the more reliable checks available to the pathologist. When the benign tissue fails to stain, the whole slide is uninterpretable — you can't distinguish real PTEN loss from a technical staining failure. That's why preanalytic factors matter so much. Fixation time, tissue age, and antigen retrieval all influence the signal, and a poorly fixed block can sink an otherwise good case.

FISH and NGS detect the genomic lesion rather than the protein. Fluorescence in situ hybridization identifies deletion of the PTEN locus, while next-generation sequencing can capture deletions, point mutations, and copy-number changes. These methods catch structural events that IHC infers only indirectly. The two approaches often agree, but not always — a tumor can lose protein expression through mechanisms a deletion-focused FISH probe won't see, and conversely a subtle genomic change may not fully abolish the protein.

For most clinical laboratories, IHC remains the pragmatic first-line tool: it's affordable, fast, preserves tissue architecture, and its internal control makes interpretation transparent.

What Each Result Means

PTEN intact. The tumor still expresses PTEN. The brake on the PI3K/AKT pathway remains in place, at least by this measure. This is the more favorable prognostic finding, though it never means a cancer is benign — plenty of aggressive tumors keep PTEN and progress through other routes.

PTEN loss. The tumor has lost PTEN expression. This is an adverse prognostic marker, associated with more aggressive disease and a higher likelihood of poor outcomes [2]. The evidence suggests PTEN loss tracks with higher-grade tumors and worse recurrence-free survival, which is why it draws attention even when the histologic grade seems reassuring.

A crucial point for trainees: PTEN loss is prognostic, not predictive, in standard practice. It tells you something about how the cancer is likely to behave — it does not, by itself, dictate a specific therapy.

What It Determines for Treatment Eligibility

Here's where the biology becomes strategically interesting. Because PTEN loss unleashes the PI3K/AKT signaling axis, tumors that have lost PTEN may depend on that pathway to survive. That dependency is a potential vulnerability. Drugs that target components of the PI3K/AKT pathway — PI3K inhibitors, AKT inhibitors, and related agents — aim to shut down the very signaling that PTEN loss has switched on [2].

So a PTEN-loss result can inform eligibility for clinical trials investigating PI3K/AKT pathway inhibitors. That's the correct framing. It's not a directive to take any particular drug; it's a molecular flag that may qualify a patient for a study or a trial cohort built around that pathway. Whether such a strategy improves outcomes is a research question, and the field is still gathering that evidence [2].

The distinction matters clinically. An oncologist reading "PTEN loss" learns two things at once — that the cancer carries an adverse prognostic signal, and that the tumor's biology points toward a druggable pathway worth exploring in the trial setting. Neither insight translates into a fixed prescription outside that context.

Caveats and What's Evolving

Several caveats deserve emphasis.

First, scoring thresholds and interpretation aren't fully standardized across laboratories. What one lab calls partial loss another might read differently, and harmonizing these calls remains a work in progress [2].

Second — and this is a big one — prostate cancer is heterogeneous. PTEN loss can be present in one focus of a tumor and absent in another within the same gland. That patchiness has direct consequences for biopsy sampling: a single core may miss a PTEN-deleted region entirely, yielding a falsely reassuring "intact" result. Sampling strategy, and awareness of this heterogeneity, shapes how confidently we can act on any single result.

Third, IHC and genomic assays don't always concur, and understanding why they diverge in a given case is part of thoughtful interpretation rather than a technical footnote.

Finally, the therapeutic side is fast-moving. The role of PI3K/AKT-directed therapy in PTEN-lost prostate cancer is an active area of investigation, and the evidence base will keep shifting [2].

The Practical Takeaway

When I see PTEN loss on a report, I read it as a signal to take the tumor more seriously than its grade alone might suggest — a prompt to weigh closer surveillance and to consider whether a PI3K/AKT-focused trial is appropriate. When PTEN is intact, that particular adverse flag is absent, though the rest of the pathology still governs the picture. Either way, the result is one input among many, most useful when integrated with grade, stage, and the clinical context rather than read in isolation.

References

1. WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours, 5th ed. IARC, Lyon; 2022. ISBN 978-92-832-4512-4.
2. Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology / PMC; 2020. PMCID: PMC7472658.